Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Finnish cancer registry [Internet]. Helsinki, Finland. 2017. [cited 2017 April 17]. Available from: http://www.cancer.fi/syoparekisteri/en/statistics/.
   Google Scholar
• Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606–1625.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Katz MH, Pisters PW, Evans BD, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–848.
   PubMed Web of Science ®Google Scholar
• Seppänen H, Juuti A, Mustonen H, et al. The results of pancreatic resections and long-term survival for pancreatic ductal adenocarcinoma: a single-institution experience. Scand J Surg. 2017;106:54–61.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17:981–990.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921.
   PubMed Web of Science ®Google Scholar
• Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. JCO. 2008;26:3496–3502.
   PubMed Web of Science ®Google Scholar
• Roland CL, Yang AD, Katz MH, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168–1175.
   PubMed Web of Science ®Google Scholar
• Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18:619–627.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. JCO. 2016;35:515–522.
   PubMed Web of Science ®Google Scholar
• De Geus SW, Eskander MF, Bliss LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: a nationwide propensity score matched analysis. Surgery. 2017;161:592–601.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic Adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.
   PubMedGoogle Scholar
• Tzeng CW, Tran Cao HS, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18:16–25.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Katz MH, Tzeng CW, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – a population-based cohort study. Acta Oncol. 2016;55:265–277.
   PubMed Web of Science ®Google Scholar
• Desai NV, Sliesoraitis S, Hughes SJ, et al. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med. 2015;4:1224–1239.
   PubMed Web of Science ®Google Scholar
• Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–1210.
   PubMed Web of Science ®Google Scholar
• Cloyd JM, Katz MH, Prakash L, et al. Preoperative therapy and pancreatoduodenectomy of pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointest Surg. 2017;21:164–174.
   PubMed Web of Science ®Google Scholar
• Youngmin H, Sun-Whe K, Jinseok H, et al. Multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreatic cancer. Oral session presented at: 51st Pancreas Club Annual meeting; 2017 May 5–6; Chicago, IL.
   Google Scholar
• Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671–1677.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with lovally advanced pancreatic cancer: an Eastern cooperative oncology group trial. JCO. 2011;29:4105–4112.
   PubMed Web of Science ®Google Scholar
• Hartwig W, Gluth A, Hinz U, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016;103:1683–1694.
   PubMed Web of Science ®Google Scholar
• Wasif N, Ko CY, Wainberg Z, et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010;17:2312–2320.
   PubMed Web of Science ®Google Scholar
• Crippa S, Partelli S, Zamboni G, et al. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery. 2012;152:S112–S119.
   PubMed Web of Science ®Google Scholar
• Åkenberg D, Ansari D, Andersson R, et al. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. WJG. 2016; 22:6424–6433.
   PubMed Web of Science ®Google Scholar
• Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014;24:105–112.
   PubMed Web of Science ®Google Scholar